NUVL
Price
$84.22
Change
+$0.36 (+0.43%)
Updated
Oct 3 closing price
Capitalization
6.07B
31 days until earnings call
PCVX
Price
$42.66
Change
+$2.53 (+6.30%)
Updated
Oct 3 closing price
Capitalization
5.54B
35 days until earnings call
Interact to see
Advertisement

NUVL vs PCVX

Header iconNUVL vs PCVX Comparison
Open Charts NUVL vs PCVXBanner chart's image
Nuvalent
Price$84.22
Change+$0.36 (+0.43%)
Volume$479.98K
Capitalization6.07B
Vaxcyte
Price$42.66
Change+$2.53 (+6.30%)
Volume$2.4M
Capitalization5.54B
NUVL vs PCVX Comparison Chart in %
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PCVX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NUVL vs. PCVX commentary
Oct 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and PCVX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 06, 2025
Stock price -- (NUVL: $84.22 vs. PCVX: $42.66)
Brand notoriety: NUVL and PCVX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 111% vs. PCVX: 140%
Market capitalization -- NUVL: $6.07B vs. PCVX: $5.54B
NUVL [@Biotechnology] is valued at $6.07B. PCVX’s [@Biotechnology] market capitalization is $5.54B. The market cap for tickers in the [@Biotechnology] industry ranges from $103.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whilePCVX’s FA Score has 0 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • PCVX’s FA Score: 0 green, 5 red.
According to our system of comparison, PCVX is a better buy in the long-term than NUVL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 7 TA indicator(s) are bullish while PCVX’s TA Score has 6 bullish TA indicator(s).

  • NUVL’s TA Score: 7 bullish, 3 bearish.
  • PCVX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than PCVX.

Price Growth

NUVL (@Biotechnology) experienced а +3.48% price change this week, while PCVX (@Biotechnology) price change was +25.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

NUVL is expected to report earnings on Nov 06, 2025.

PCVX is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($6.07B) has a higher market cap than PCVX($5.54B). NUVL YTD gains are higher at: 7.588 vs. PCVX (-47.887). NUVL has higher annual earnings (EBITDA): -362.01M vs. PCVX (-584.35M). PCVX has more cash in the bank: 1.66B vs. NUVL (1.01B). NUVL (0) and PCVX (0) have equivalent revenues.
NUVLPCVXNUVL / PCVX
Capitalization6.07B5.54B110%
EBITDA-362.01M-584.35M62%
Gain YTD7.588-47.887-16%
P/E RatioN/AN/A-
Revenue00-
Total Cash1.01B1.66B61%
Total DebtN/A85.8M-
TECHNICAL ANALYSIS
Technical Analysis
NUVLPCVX
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
75%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 11 days ago
78%
Bearish Trend 11 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PCVX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DVFYX79.620.34
+0.43%
Davis Financial Y
RISAX28.690.12
+0.42%
Manning & Napier Rainier Intl Discv S
RMFAX61.890.24
+0.39%
American Funds American Mutual R1
COMZX31.29-0.08
-0.26%
DWS Digital Horizons Inst
FMGGX51.20-0.17
-0.33%
Franklin Small-Mid Cap Growth R6

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XENE. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+0.43%
XENE - NUVL
62%
Loosely correlated
+1.05%
CGON - NUVL
59%
Loosely correlated
-0.09%
RVMD - NUVL
59%
Loosely correlated
+2.21%
IDYA - NUVL
57%
Loosely correlated
+1.62%
NRIX - NUVL
57%
Loosely correlated
+3.30%
More

PCVX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PCVX has been loosely correlated with NUVL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PCVX jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCVX
1D Price
Change %
PCVX100%
+6.30%
NUVL - PCVX
47%
Loosely correlated
+0.43%
KYMR - PCVX
46%
Loosely correlated
+3.39%
BEAM - PCVX
46%
Loosely correlated
+0.63%
SYRE - PCVX
46%
Loosely correlated
-0.56%
IDYA - PCVX
45%
Loosely correlated
+1.62%
More